Skip to Content
Merck

D7777

Dulbecco′s Modified Eagle′s Medium - high glucose

With 4500 mg/L glucose, L-glutamine, and sodium pyruvate, without sodium bicarbonate, powder, suitable for cell culture

Synonym(s):

DME, DMEM

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

NACRES:
NA.75
UNSPSC Code:
12352207

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Dulbecco′s Modified Eagle′s Medium - high glucose, With 4500 mg/L glucose, L-glutamine, and sodium pyruvate, without sodium bicarbonate, powder, suitable for cell culture

form

powder

technique(s)

cell culture | mammalian: suitable

components

glucose: high
sodium pyruvate: yes
NaHCO3: no
HEPES: no
phenol red: yes
L-glutamine: yes

shipped in

ambient

storage temp.

2-8°C

Quality Level

500

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Dulbecco′s Modified Eagle′s Medium (DMEM) is a modification of Basal Medium Eagle (BME) that contains four-fold concentrations of the amino acids and vitamins. The original formulation contained 1000 mg/L of glucose and was used to culture embryonic mouse cells. Since then, it has been modified in several ways to support primary cultures of mouse and chicken cells, as well as a variety of normal and transformed cells. Each of these media offers a different combination of L-glutamine and sodium pyruvate. Additionally, the glucose levels have been raised to 4500 mg/L, contributing to the name "DMEM/High".

Preparation Note

Formulated to contain 13.5 grams of powder per liter of medium.
Supplement with 3.7 g/L sodium bicarbonate

Storage Class

13 - Non Combustible Solids

wgk

WGK 1

Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

Substances Subject to be Indicated Names

ishl_indicated

Substances Subject to be Notified Names

ishl_notified

D7777LF1-BIBC: + D7777-50K: + D7777-50KG: + D7777-10L: + D7777-VAR: + D7777-25KGS: + D7777-25K: + D7777-BIBC: + D7777-BULK: + D7777-2X5L: + D7777-1L: + D7777-25KG: + D7777-10X1L: + D7777-PROC: + D7777-50L:

jan

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
25E403
25E403
0000447953
0000447953
0000441380

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Assaf Almog et al.
PLoS computational biology, 15(5), e1006934-e1006934 (2019-05-03)
Neural systems are organized in a modular way, serving multiple functionalities. This multiplicity requires that both positive (e.g. excitatory, phase-coherent) and negative (e.g. inhibitory, phase-opposing) interactions take place across brain modules. Unfortunately, most methods to detect modules from time series
Megan E Muroski et al.
Journal of the American Chemical Society, 136(42), 14763-14771 (2014-09-10)
Mesenchymal stem cells (MSC) have been identified as having great potential as autologous cell therapeutics to treat traumatic brain injury and spinal injury as well as neuronal and cardiac ischemic events. All future clinical applications of MSC cell therapies must
Jie Wang et al.
Molecular medicine reports, 22(2), 1111-1118 (2020-07-07)
Neuromyelitis optica (NMO) is a severe neurological demyelinating autoimmune disease that affects the optic nerves and spinal cord. There is currently no effective cure or therapy. Aquaporin‑4 (AQP4) is a known target of the autoimmune antibody NMO‑IgG. Therefore, binding of
Emilia Galli et al.
Cell transplantation, 28(4), 413-424 (2019-03-08)
Cerebral dopamine neurotrophic factor (CDNF) shows beneficial effects in rodent models of Parkinson's and Alzheimer's disease. The brain is a challenging target for protein therapy due to its exclusive blood-brain barrier. Hence, the therapeutic protein should be delivered directly to
Maria H Jäntti et al.
FEBS open bio, 8(5), 817-828 (2018-05-11)
Prostate cancer is one of the most common cancers in men. Although it has a relatively high 5-year survival rate, development of resistance to standard androgen-deprivation therapy is a significant clinical problem. Therefore, novel therapeutic strategies are urgently needed. The
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service